RBC Capital analyst Brian Abrahams maintained a Hold rating on Pliant Therapeutics (PLRX – Research Report) yesterday and set a price target of ...

Wells Fargo analyst Tiago Fauth maintained a Hold rating on Pliant Therapeutics (PLRX – Research Report) today and set a price target of $3.00.

2seventy bio Inc (TSVT) is expected to report $-0.20 for 4Q. 908 Devices Inc (MASS) is expected to report $-0.39 for 4Q. ATN International Inc (ATNI) is expected to report $-0.24 for 4Q. Aclaris ...

While architectural, museum-worthy nail art is a delight to behold and just as fun to wear, some folks are in the camp of ...

As Meghan’s new Netflix show airs for the first time, Tanya Gold explores the complex, heart-breaking and deeply unhealthy ...

Callista’s hobo bag has all the storage you’d ever need. Perfect for pocket-lovers, this bag ensures all your daily ...

Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q4 earnings. Here is a breakdown of the information Pliant Therapeutics, Inc. presented to ...

SOUTH SAN FRANCISCO - Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported fourth quarter earnings that beat analyst estimates, sending shares up 6.5% in after-hours trading. The cli ...

The transition went into effect in these markets on March 1, 2025, after the successful launch of LV360 into Canada, Mexico, ...

Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...

Environmental activist Greta Thunberg spawned a new generation of youth eager to combat climate change. Foresight narratives ...

Getting rid of the military’s top lawyers is not exactly a sign that the Trump administration wants to follow the law.